Canakinumab
Common brands: Ilaris, Kineret, Methotrexate, Actemra, Rasuvo
Top reporter: Novartis Pharmaceuticals Corporation
Corticosteroid [EPC]Interleukin-1 Receptor Antagonist [EPC]Interleukin-6 Receptor Antagonist [EPC]Folate Analog Metabolic Inhibitor [EPC]Tumor Necrosis Factor Blocker [EPC]
10,642
Total Reports
4,207
Serious Reports
466
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (4.38%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Canakinumab.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | PYREXIA | 1,415 | |
| 2 | INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION | 1,242 | |
| 3 | DRUG INEFFECTIVE | 1,195 | |
| 4 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 954 | |
| 5 | PAIN | 937 | |
| 6 | CONDITION AGGRAVATED | 853 | |
| 7 | MALAISE | 721 | |
| 8 | OFF LABEL USE | 693 | |
| 9 | ARTHRALGIA | 606 | |
| 10 | RASH | 561 | |
| 11 | INCORRECT DOSE ADMINISTERED | 502 | |
| 12 | JOINT SWELLING | 487 | |
| 13 | HEADACHE | 438 | |
| 14 | FATIGUE | 389 | |
| 15 | PULMONARY EMBOLISM | 387 | |
| 16 | DIVERTICULITIS | 381 | |
| 17 | RENAL FAILURE | 375 | |
| 18 | DEEP VEIN THROMBOSIS | 336 | |
| 19 | COUGH | 330 | |
| 20 | PNEUMONIA | 330 | |
| 21 | PRODUCT USE IN UNAPPROVED INDICATION | 330 | |
| 22 | APPARENT DEATH | 324 | |
| 23 | C-REACTIVE PROTEIN INCREASED | 316 | |
| 24 | COVID-19 | 310 | |
| 25 | SEPSIS | 308 | |
| 26 | VOMITING | 299 | |
| 27 | URTICARIA | 298 | |
| 28 | DIARRHOEA | 293 | |
| 29 | ABDOMINAL PAIN | 280 | |
| 30 | ILLNESS | 278 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.